scholarly journals An Ex Vivo Fermentation Screening Platform to Study Drug Metabolism by Human Gut Microbiota

2018 ◽  
Vol 46 (11) ◽  
pp. 1596-1607 ◽  
Author(s):  
E. van de Steeg ◽  
F. H. J. Schuren ◽  
R. Scott Obach ◽  
C. van Woudenbergh ◽  
Gregory S. Walker ◽  
...  
mBio ◽  
2020 ◽  
Vol 11 (5) ◽  
Author(s):  
Xiaoqian Yu ◽  
Thomas Gurry ◽  
Le Thanh Tu Nguyen ◽  
Hunter S. Richardson ◽  
Eric J. Alm

ABSTRACT Prebiotics confer benefits to human health, often by promoting the growth of gut bacteria that produce metabolites valuable to the human body, such as short-chain fatty acids (SCFAs). While prebiotic selection has strongly focused on maximizing the production of SCFAs, less attention has been paid to gases, a by-product of SCFA production that also has physiological effects on the human body. Here, we investigate how the content and volume of gas production by human gut microbiota are affected by the chemical composition of the prebiotic and the community composition of the microbiota. We first constructed a linear system model based on mass and electron balance and compared the theoretical product ranges of two prebiotics, inulin and pectin. Modeling shows that pectin is more restricted in product space, with less potential for H2 but more potential for CO2 production. An ex vivo experimental system showed pectin degradation produced significantly less H2 than inulin, but CO2 production fell outside the theoretical product range, suggesting fermentation of fecal debris. Microbial community composition also impacted results: methane production was dependent on the presence of Methanobacteria, while interindividual differences in H2 production during inulin degradation were driven by a Lachnospiraceae taxon. Overall, these results suggest that both the chemistry of the prebiotic and the composition of the microbiota are relevant to gas production. Metabolic processes that are relatively prevalent in the microbiome, such as H2 production, will depend more on substrate, while rare metabolisms such as methanogenesis depend more strongly on microbiome composition. IMPORTANCE Prebiotic fermentation in the gut often leads to the coproduction of short-chain fatty acids (SCFAs) and gases. While excess gas production can be a potential problem for those with functional gut disorders, gas production is rarely considered during prebiotic design. In this study, we combined the use of theoretical models and an ex vivo experimental platform to illustrate that both the chemical composition of the prebiotic and the community composition of the human gut microbiota can affect the volume and content of gas production during prebiotic fermentation. Specifically, more prevalent metabolic processes such as hydrogen production were strongly affected by the oxidation state of the probiotic, while rare metabolisms such as methane production were less affected by the chemical nature of the substrate and entirely dependent on the presence of Methanobacteria in the microbiota.


Planta Medica ◽  
2016 ◽  
Vol 81 (S 01) ◽  
pp. S1-S381
Author(s):  
JP Piwowarski ◽  
S Granica ◽  
J Stefańska ◽  
AK Kiss

2018 ◽  
Vol 33 (1) ◽  
pp. S81-S82
Author(s):  
Steven Erpelinck ◽  
Frank H.J. Schuren ◽  
Irene H.G. Nooijen ◽  
R. Scott Obach ◽  
Gregory S. Walker ◽  
...  

2014 ◽  
Vol 73 (OCE1) ◽  
Author(s):  
L. Kellingray ◽  
S. Saha ◽  
J. Doleman ◽  
A. Narbad ◽  
R. Mithen

Author(s):  
Thomas Gurry ◽  
Le Thanh Tu Nguyen ◽  
Xiaoqian Yu ◽  
Eric J Alm

AbstractThe human gut microbiota is known for its highly heterogeneous composition across different individuals. However, relatively little is known about functional differences in its ability to ferment complex polysaccharides. Through ex vivo measurements from healthy human donors, we show that individuals vary markedly in their microbial metabolic phenotypes (MMPs), mirroring differences in their microbiota composition, and resulting in the production of different quantities and proportions of Short Chain Fatty Acids (SCFAs) from the same inputs. We also show that aspects of these MMPs can be predicted from composition using 16S rRNA sequencing. From experiments performed using the same dietary fibers in vivo, we demonstrate that an ingested bolus of fiber is almost entirely consumed by the microbiota upon passage. We leverage our ex vivo data to construct a model of SCFA production and absorption in vivo, and argue that inter-individual differences in quantities of absorbed SCFA are directly related to differences in production. Taken together, these data suggest that personalized dietary fiber supplementation based on an individual’s MMP is an attractive therapeutic strategy for treating diseases associated with SCFA production.


2020 ◽  
Author(s):  
Antonella Riva ◽  
Valeria Longo ◽  
Davide Berlanda ◽  
Pietro Allegrini ◽  
Giulia Masetti ◽  
...  

Abstract Background: The present study aimed to evaluate the effects of a new food-grade bioavailable delivery system of bergamot on human gut microbiota, in order to demonstrate the potential correlation of microbiota modulation in cardiovascular health.The identification of human gut microbiota modification was performed after ex-vivo incubation with bergamot phytosome (Vazguard™) of individual faecal slurries from healthy women (45–53 years) as follows: after incubation at 37°C in anaerobic condition, DNA was extracted and a 16S Metagenomic Sequencing Analysis performed. Results: Twenty-five different phyla were identified, among which 4 were modulated: Firmicutes, Proteobacteria, Bacteroidetes, Actinobacteria. The decreased Firmicutes/Bacteroidetes ratio and the increase of Proteobacteria were observed indicating a positive modulation of microbiota possibly linked to cardiovascular health. 418 different genera were also identified, among which several of them were mildly modulated.Conclusions: For the first time, a gut microbiome modulation was associated to the new delivery system of bergamot phytosome, supporting its clinical efficacy for cardiovascular health. New potential applications in weight control and gastrointestinal benefits were suggested.


2016 ◽  
Vol 79 (12) ◽  
pp. 3022-3030 ◽  
Author(s):  
Jakub P. Piwowarski ◽  
Sebastian Granica ◽  
Joanna Stefańska ◽  
Anna K. Kiss

PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254004
Author(s):  
Thomas Gurry ◽  
Le Thanh Tu Nguyen ◽  
Xiaoqian Yu ◽  
Eric J. Alm

The human gut microbiota is known for its highly heterogeneous composition across different individuals. However, relatively little is known about functional differences in its ability to ferment complex polysaccharides. Through ex vivo measurements from healthy human donors, we show that individuals vary markedly in their microbial metabolic phenotypes (MMPs), mirroring differences in their microbiota composition, and resulting in the production of different quantities and proportions of Short Chain Fatty Acids (SCFAs) from the same inputs. We also show that aspects of these MMPs can be predicted from composition using 16S rRNA sequencing. From experiments performed using the same dietary fibers in vivo, we demonstrate that an ingested bolus of fiber is almost entirely consumed by the microbiota upon passage. We leverage our ex vivo data to construct a model of SCFA production and absorption in vivo, and argue that inter-individual differences in quantities of absorbed SCFA are directly related to differences in production. Though in vivo studies are required to confirm these data in the context of the gut, in addition to in vivo read outs of SCFAs produced in response to specific fiber spike-ins, these data suggest that optimizing SCFA production in a given individual through targeted fiber supplementation requires quantitative understanding of their MMP.


2019 ◽  
Author(s):  
Renuka R. Nayak ◽  
Margaret Alexander ◽  
Kye Stapleton-Grey ◽  
Carles Ubeda ◽  
Jose U. Scher ◽  
...  

AbstractThe trillions of microorganisms (microbiota) found within the human gut play a critical role in shaping the immune system, yet these complex microbial communities are also highly sensitive to numerous environmental factors. While much of the focus to date has been on dietary intake, emerging data has begun to suggest that the use of pharmaceutical drugs, even those that are not considered to be antibiotics, can alter the human gut microbiota with unknown consequences for treatment outcomes. Here, we use a combination ofin vitro, in vivo, andex vivomethods to demonstrate that the first-line therapy for rheumatoid arthritis (RA), methotrexate (MTX), has off-target effects on the human gut microbiota, resulting in a significant growth advantage for drug-resistant Firmicutes over the Bacteroidetes, which tend to be more sensitive. Longitudinal analyses of the gut microbiotas of RA patients revealed that MTX-induced shifts in bacterial relative abundance are associated with improved drug response and transplant experiments in gnotobiotic mice show that these shifts lead to reduced inflammation. Together, these results suggest that the mechanism-of-action of non-antibiotic drugs may be due in part to off-target effects on the gut microbiota, while providing a critical first step towards explaining long-standing differences in drug response between patients.


Sign in / Sign up

Export Citation Format

Share Document